Connecticut 2018 Regular Session

Connecticut House Bill HB05384

Introduced
3/1/18  
Refer
3/1/18  
Refer
3/1/18  
Report Pass
3/20/18  
Refer
4/2/18  
Refer
4/2/18  
Report Pass
4/9/18  
Report Pass
4/9/18  
Engrossed
5/4/18  
Engrossed
5/4/18  
Report Pass
5/5/18  
Report Pass
5/5/18  
Chaptered
5/17/18  
Enrolled
5/18/18  

Caption

An Act Concerning Prescription Drug Costs.

Companion Bills

No companion bills found.

Previously Filed As

CT SB00008

An Act Concerning Drug Affordability.

CT SB00133

An Act Concerning Regulation Of Prescription Drugs And Related Professions.

CT SB00400

An Act Concerning The Insurance Department's Technical Corrections And Other Revisions To The Insurance Statutes.

CT SB00202

An Act Concerning The Department Of Consumer Protection's Recommendations Regarding Prescription Drug Control.

CT HB05503

An Act Concerning Insurance Market Conduct And Insurance Licensing, The Insurance Department's Technical Corrections And Other Revisions To The Insurance Statutes And Captive Insurance.

CT SB00182

An Act Prohibiting Certain Health Carriers From Requiring Step Therapy For Prescription Drugs Used To Treat A Mental Or Behavioral Health Condition Or A Chronic, Disabling Or Life-threatening Condition.

CT SB00242

An Act Concerning The Office Of Health Strategy's Recommendations Regarding The All-payer Claims Database.

CT SB00210

An Act Concerning A State-operated Reinsurance Program, Health Care Cost Growth And Site Of Service Billing Requirements.

CT HB05054

An Act Addressing Health Care Affordability.

CT HB05248

An Act Concerning Health Benefit Review.

Similar Bills

MS SB2012

Mississippi Health Care Cost Transparency Act; enact.

TX HB2536

Relating to transparency related to drug costs.

CT HB06870

An Act Addressing Patients' Prescription Drug Costs.

CT SB00013

An Act Reducing Prescription Drug Prices.

CT SB00011

An Act Concerning Prescription Drug Access And Affordability.

NJ S1390

Requires carriers to pass prescription drug savings to consumers.

HI HB24

Relating To Pharmacy Benefit Managers.

MA S2492

Relative to pharmaceutical access, costs and transparency